PPBT — Purple Biotech Balance Sheet
0.000.00%
Last trade - 00:00- $5.49m
- -$0.28m
Annual balance sheet for Purple Biotech, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 20-F | 20-F | 20-F | 20-F | 20-F |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 57.8 | 47.2 | 32.1 | 15.4 | 8.52 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 0.5 | 0 | — | — | — |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 59.3 | 48.5 | 33.3 | 15.8 | 8.91 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 0.968 | 0.896 | 0.682 | 0.47 | 0.288 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 83.8 | 70.2 | 54.6 | 44.3 | 37 |
| Accounts Payable | |||||
| Payable / Accrued | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 3.1 | 4.25 | 7.06 | 7.18 | 3.99 |
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 4.41 | 5.37 | 7.71 | 10.1 | 4.18 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 79.4 | 64.8 | 46.9 | 34.2 | 32.9 |
| Total Liabilities & Shareholders' Equity | 83.8 | 70.2 | 54.6 | 44.3 | 37 |
| Total Common Shares Outstanding |